January 4, 2016 Charlottesville, VA
The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health has awarded the Center for Diabetes Technology, led by researcher Dr. Boris Kovatchev, $12.7 million dollars for two finalizing trials of the Artificial Pancreas.
The first of these trials – the International Diabetes Closed-Loop (IDCL) Trial will recruit 240 people with type 1 diabetes, each of whom will spend 6 months in the study. The IDCL Trial will test artificial pancreas technology developed by researchers at the UVA School of Medicine and School of Engineering and Applied Sciences and will compare the effectiveness of an unassisted pump and sensor to control blood sugars with the safety and efficacy of the Artificial Pancreas system.
The second trial – the Enhanced Control-to-Range (ECTR) study – will test technology developed by our colleagues led by Dr. Francis Doyle III at the Harvard John A. Paulson School of Engineering and Applied Sciences to see whether the algorithm can further improve blood sugar control. The ECTR study will use a subset of the population from the first trial.
In both studies, people with Type 1 Diabetes will carry their daily lives while wearing the Artificial Pancreas. UVA will be working with Type Zero – a startup company in Charlottesville, VA that licensed the UVA technology and will contribute their InControl software to the IDCL trial.
The following research sites will participate in the IDCL trial: the University of Virginia (Charlottesville, VA), Harvard University (Cambridge, MA); the Icahn School of Medicine at Mount Sinai (New York City, NY); the Mayo Clinic (Rochester, MN); the University of Colorado (Denver, CO); Stanford University, California ; the University of Montpellier in France; the University of Padova in Italy; the Academic Medical Center of Amsterdam in the Netherlands, and the William Sansum Diabetes Center (Santa Barbara, CA). The IDCL trial will be coordinated by the Jaeb Center for Health research, Tampa, FL.
Click here for the full article from the University of Virginia, and see further coverage from the Richmond Daily Progress
Are you a Type 1 Diabetic interested in participating in this and other exciting trials to move treatment forward? Click here to contact us!
Tags: artificial pancreas, clinical trials, funding
Comments